Business

Know the Business

Elevance Health is a $198B-revenue managed-care utility that takes in premiums and government capitation, pays out roughly 87 cents of every dollar as medical claims, and earns a thin spread on the rest. The economics are simple but the cycle is brutal: the company is currently in a margin trough — operating margin has compressed from 5.5% in FY2018 to 3.3% in FY2025 — driven by Medicaid eligibility redeterminations, Medicare Advantage rate pressure, and elevated medical-cost trend. The market is pricing recovery (P/E 13.9× and P/B 1.76× — both at multi-year lows), so the central question is not "is the business broken" but "is the trough as deep as guidance implies, and how clean is the snap-back."

1. How This Business Actually Works

Elevance is a regulated spread business: it collects premiums (and government capitation), pools them, pays claims, and keeps the difference. About 87 cents of every revenue dollar goes straight back out as medical claims (the "benefit expense ratio"), another ~10 cents fund SG&A and technology, leaving roughly 3 cents of operating profit. There is no real product margin to defend — the entire game is predicting medical-cost trend correctly when prices are set, then managing the inevitable variance through reserves, network discounts, and utilization management.

The economics produce three structural truths that drive everything else.

Float and timing. Premiums arrive monthly; claims pay out with a lag. Days in Claims Payable was 46.6 days at Q1 FY2026 — meaning the company is sitting on roughly six weeks of unpaid claims as a revolving liability. That float earns investment income and is the reason cash conversion (operating cash flow $4.3B in a single quarter) exceeds GAAP earnings. It is also why a small mis-estimate of incurred-but-not-reported claims at year-end can swing reported margins meaningfully — the FY2024 → FY2025 operating-income decline from $7.28B to $6.57B was almost entirely a trend-versus-pricing miss in Medicaid and Medicare Advantage.

Bargaining power runs through the BCBS license, not the brand. Elevance is the exclusive Blue Cross or Blue Cross/Blue Shield licensee in 14 states (including California, New York, Georgia, Ohio, Virginia). That license gives it three things: (1) the largest local provider-discount schedules in those states because it owns the volume, (2) access to the BlueCard reciprocity network that lets multi-state employers buy a single plan, and (3) regulatory and political moat — a new entrant would have to replicate networks state-by-state. The Carelon services arm (pharmacy, behavioral health, post-acute, analytics — $18.7B revenue, +27% in 2025) is being built explicitly as the Optum analog: take the captive Health Benefits volume, layer higher-margin services on top, then sell those services externally.

Where incremental profit actually comes from. Not premium growth. Premium growth typically gets re-priced to a target medical loss ratio (MLR), so the dollar-for-dollar gain is small. Real incremental profit comes from (a) Medicare Advantage Star Ratings — every member in a 4+ Star plan unlocks ~5% bonus payments from CMS — Elevance jumped from 40% of members at 4+ Stars in 2025 to 59% in 2026 ratings, a meaningful 2027 tailwind; (b) Carelon services revenue, where margins are several hundred basis points higher than insurance; and (c) capital returns — the company has retired roughly 4% of shares each year, turning even flat operating profit into per-share growth.

2. The Playing Field

Elevance is the #2 managed-care company by revenue but a distant #2 by market value, trading at the lowest multiples in the peer set. Among "real" peers — companies that actually compete for the same members and contracts — UNH is in a different gravity well, and the rest are smaller or more specialized.

A few things the peer set reveals.

Elevance and Cigna look statistically identical and are both being valued like cyclical bottoms. Both run ~3.3% operating margins, both trade in the 12–14× P/E range, both generate strong free cash flow, and both have ROEs in the 13–15% range. The market is treating them as commodities. UNH still trades at a premium (25× P/E, 3.2× book) despite having matched ELV's operating margin — investors are paying for the Optum services moat, not for the insurance business.

The "good" managed-care company runs ~5% operating margins. ELV's own FY2018 was 5.5%, UNH's FY2018-2022 average was 6%+. Anything below 4% is a stress signal — and right now ELV, CI, CVS, HUM, MOH are all there. The cycle is hitting the entire industry, not Elevance specifically.

The pure-plays are the warning signal. CNC and MOH are the canaries — both Medicaid-heavy, and CNC's loss of $6.7B in FY2025 (-29% ROE) is what happens when redetermination plus rate inadequacy bites without a diversified book to absorb it. ELV's exposure is meaningful but partial: Medicaid is roughly 25–30% of premium revenue, mixed with commercial and Medicare. That is the diversification advantage to value here.

3. Is This Business Cyclical?

Yes — but the cycle is regulatory and underwriting, not macroeconomic. Revenue barely flinches in a recession (premiums are contractual; Medicaid actually grows) but operating income is highly cyclical because medical-cost trend, pricing adequacy, and government rate-setting move in 2–3 year waves that the industry cannot perfectly hedge.

Three downturns since 2005 are instructive.

2008–2009 financial crisis. Operating margin compressed from 7.8% to 6.0% — a 180 bps hit — driven by employer-group attrition (commercial members lost jobs) and adverse selection in individual plans. Recovery took two years; revenue didn't actually grow until 2013. The lesson: macro recessions hit the commercial book through employment, not through utilization.

2017 ACA reset. Margin dipped to 4.5% as the company exited unprofitable individual exchange markets and absorbed the health insurer fee. The company then re-entered exchanges selectively after the rules stabilized. Recovery to 5.5% took one year.

2024–2026 cycle (the current one). Margin compressed from 4.5% in 2023 to 3.3% in 2025 — a 120 bps hit and the lowest level in 20 years. Three forces are stacked: (1) Medicaid eligibility redeterminations after the COVID public health emergency ended ~$2 trillion of automatic re-enrollment, leaving a sicker remaining pool whose acuity wasn't priced in; (2) CMS Medicare Advantage rate cuts in 2024–2025 baseline reset that the industry is still working through; (3) elevated post-COVID utilization, particularly behavioral health and specialty pharmacy. Management calls FY2026 the "trough year" with Medicaid operating margin guided to negative 1.75% before recovery to a 12%+ EPS growth trajectory in FY2027.

The pattern across all three: revenue does not contract, margin does, and the recovery comes when the company re-prices into the next contract cycle (12–24 months). This is why the equity is now trading at 1.8× book — the market is paying for cycle-bottom assets, not for a broken franchise.

4. The Metrics That Actually Matter

Forget the headline P/E and revenue growth. Five metrics drive value creation in this business, and most matter only at certain points in the cycle.

5. What I'd Tell a Young Analyst

Three things, in order of importance.

Watch the benefit expense ratio quarterly, not the EPS. Every other line item is downstream of MLR. When management raises the FY2026 EPS guide from $25.75 to $26.75 in Q1, the only thing you need to verify in subsequent quarters is whether 86.8% holds. If MLR creeps to 88%, the guide is gone regardless of any "AI productivity" story. If it drifts to 85%, the next problem is a regulatory rebate, not an earnings miss.

Distinguish three things investors and management constantly conflate. (1) Medicaid acuity normalization — temporary, prices fix it in the 2026 rate cycle. (2) Medicare Advantage Star Ratings recovery — real and durable, locked in for 2027 by the October 2025 ratings already published. (3) Carelon margin expansion — strategic but unproven; CarelonRx still leans heavily on the CVS Caremark agreement that runs through 2027. The first two together are probably worth most of the bull case to the 2027 EPS bridge. Don't pay for the third one until you see external (non-captive) Carelon revenue grow at materially above the captive book.

The single thing the market may be most wrong about: the $935M CMS RADV accrual recorded in Q1 FY2026. It's been excluded from adjusted earnings, but if the eventual settlement is materially higher — or if it sets a methodology that affects future risk-adjustment payments — the recurring annual cost is the part to worry about, not the one-time charge. The bears will treat this as the start of a multi-year regulatory haircut to MA economics across the industry. The bulls will treat it as a one-time legacy cleanup. Both views are defensible, and you cannot resolve it from filings alone — track the proposed CMS RADV final rule and any peer disclosures (UNH especially) before sizing it.

What would change the thesis outright: a sustained MLR above 88% for two consecutive quarters with no offsetting pricing path, a downgrade in the 2027 Star Ratings methodology, or a Carelon external customer loss (especially the affiliated health-plan PBM contracts). Any one of those breaks the recovery story; absent them, the cycle math is doing the work.